Sacituzumab govitecan in HR+ and HER2- metastatic breast cancer: for all or for some?

There is an undisputable need for new treatment options in endocrine-resistant hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+ and HER2–) metastatic breast cancer that is resistant to conventional therapies. Expectations concerning effective new agents are high, especially after the successful introduction of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors as first-line and second-line treatments in metastatic breast cancer. 1 Piezzo M Chiodini P Riemma M et al. Progression-free survival and overall survival of CDK 4/6 inhibitors plus endocrine therapy in metastatic breast cancer: a systematic review and meta-analysis. Int J Mol Sci. 2020; 21: 17 Crossref Scopus (41) Google Scholar Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trialSacituzumab govitecan demonstrated statistically significant and clinically meaningful benefit over chemotherapy, with a 3·2-month median overall survival improvement and a manageable safety profile. These data support sacituzumab govitecan as a new treatment option for patients with pretreated, endocrine-resistant HR+ and HER2– metastatic breast cancer. Full-Text PDF Open Access